Iveric Bio Inc Expected To Post A Loss Of 40 Cents A Share: Earnings Preview

IVERIC bio

01/11/2022 18:37

* IVERIC bio Inc  ISEE.OQ   ISEE.O  is expected to show no
change
in quarterly revenue when it reports  results on November 3. 
    * 
    * ​Refinitiv's mean analyst estimate for IVERIC bio Inc is
for a
loss of 40 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 11 "strong buy" or "buy," no
"hold" and 1 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for IVERIC bio
Inc is
$29.5​, above​ its last closing price of $23.92. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2022  -0.31       -0.31      -0.41     Missed  -30.4
 Mar. 31 2022  -0.29       -0.29      -0.29     Met     1.1
 Dec. 31 2021  -0.24       -0.25      -0.29     Missed  -18.2​
 Sep. 30 2021  -0.29       -0.29      -0.23     Beat    20.1
 ​​Jun.        -0.26       -0.26      -0.32     Missed  -22.8
 30 2021                                                
 Mar. 31 2021  -0.25       -0.25      -0.29     Missed  -16.5​
 Dec. 31 2020              -0.26      -0.27     Missed  -5.5
 Sep. 30 2020  -0.22       -0.22      -0.27     Missed  -23.6
 This summary was machine generated November 1 at 18:37 GMT.  All
figures in US dollars  unless otherwise stated